STOPCAP 1 (M1), docetaxel, systematic review and individual participant data meta-analysis

What was this study about?

What difference did this study make?

This study found that adding docetaxel to hormone therapy was more beneficial for some people with advanced prostate cancer than others. 

Docetaxel was more effective for people who had metastases in organs including their liver or lungs, or at least 4 bone metastases (“high-volume” disease).  Potentially, the benefit was even greater if they also had a large tumour in their prostate, with 55 out of 100 people who received docetaxel and hormone therapy alive after 5 years compared with 20 out of 100 who received hormone therapy only.

People who developed fewer than 4 bone metastases (“low-volume” disease) after being diagnosed with localised prostate cancer did not benefit at all from docetaxel.  At 5 years, 72 out of 100 were alive whether they received docetaxel or not. Such patients could be treated differently and spared the significant side effects of docetaxel.

These results can help inform decisions around the use of upfront docetaxel in people with metastatic prostate cancer that is still responding to hormone therapy.

Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023;24(7):783-97.

STOPCAP 1 (M1) IPD protocol

Type of study

Meta-analyses

Contact details

mrcctu.stopcapm1@ucl.ac.uk

Who funded the study?

STOPCAP 1 was funded by Prostate Cancer UK.